

SUB
B1
CON'd.

administering to said host an effective amount of an agent which at least reduces the amount of plasma active apoE in said host by an amount sufficient to reduce VLDL production in said host to reduce the plasma level of VLDL in said host.

2. The method according to Claim 1, wherein said agent inhibits apoE.
3. The method according to Claim 1, wherein said agent reduces expression of apoE.
4. The method according to Claim 1, wherein said apoE is apoE3.

5. (Amended) A method of treating a host suffering from a disease condition associated with elevated plasma levels of VLDL, said method comprising:

A 3
SUB
B2

administering to said host an effective amount of an agent that at least reduces the plasma amount of active apoE in said host by an amount sufficient to reduce VLDL production to treat said disease condition.

6. The method according to Claim 5, wherein said disease condition is a hyperlipidemia.
7. The method according to Claim 6, wherein said hyperlipidemia is Type IV hyperlipidemia.
8. The method according to Claim 6, wherein said hyperlipidemia is Type IIb hyperlipidemia.
9. The method according to Claim 5, wherein said agent inhibits said apoE.
10. The method according to Claim 5, wherein said agent reduces expression of said apoE.
11. The method according to Claim 5, wherein said apoE is apoE3.

REMARKS UNDER 37 CFR § 1.111

Claims 1-11 are pending after entry of the amendments set forth herein.

Claims 1-11 were examined and were rejected.